Biobank for patients with autoimmune disease, especially autoimmune liver disease

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00031385

Enrollment

200

Registered

2023-03-22

Start date

2023-04-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

K70-K77

Interventions

Group 1: Data i. Bibliographic data: Gender, year of birth, month of birth, date of diagnosis. ii. Data on lifestyle: Nicotine use, alcohol use, height, weight. iii. Laboratory data: Platelet count, b

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Diagnosis of autoimmune (liver)disease liver biopsy as part of clinical work up informed consent

Exclusion criteria

Exclusion criteria: <18 unwilling/no consent

Design outcomes

Primary

Measure	Time frame
i. Absolute and relative changes in standard laboratory tests for liver function or immune function. ii. Proportion of patients with treatment response during ongoing therapy. iii. Development of clinical scoring systems during the observation period. iv. Comparison and evaluation of new diagnostic systems. v. The occurrence of one of the following events: Death Liver transplantation MELD score > 15 Treatment-refractory ascites Hospitalization for one of the following reasons: a. Variceal bleeding b. Overt hepatic encephalopathy c. Spontaneous bacterial peritonitis d. Hepatocellular carcinoma e. Development of advanced fibrosis or cirrhosis (confirmed by biopsy, transient elastography, or risk models) f. Recurrence of autoimmune liver disease after liver transplantation as well as graft failure.	—

Measure

Time frame

i. Absolute and relative changes in standard laboratory tests for liver function or immune function. ii. Proportion of patients with treatment response during ongoing therapy. iii. Development of clinical scoring systems during the observation period. iv. Comparison and evaluation of new diagnostic systems. v. The occurrence of one of the following events: Death Liver transplantation MELD score > 15 Treatment-refractory ascites Hospitalization for one of the following reasons: a. Variceal bleeding b. Overt hepatic encephalopathy c. Spontaneous bacterial peritonitis d. Hepatocellular carcinoma e. Development of advanced fibrosis or cirrhosis (confirmed by biopsy, transient elastography, or risk models) f. Recurrence of autoimmune liver disease after liver transplantation as well as graft failure.

—

Secondary

Measure	Time frame
no defined outcomes	—

Countries

Germany

Contacts

Public ContactTony Bruns

Universitätsklinikum Aachen

tbruns@ukaachen.de0241/800

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026